A patient with advanced hepatocellular carcinoma (liver cancer) who participated in the Phase II trials of namodenoson from Israel’s Can-Fite (see here previously) had an extremely good response. His liver function returned to normal, and he is looking forward to … Continue reading →

Israel’s Can-Fite (see here previously) is developing small molecule medicines that address oncology and inflammatory diseases. It has partnered with Collaborations Pharma to use AI and Machine Learning techniques that significantly reduce development time and costs. https://ir.canfite.com/news-events/press-releases/detail/1032/can-fite-to-harness-artificial-intelligence-to-develop

One of the treatments being developed by Israel’s Can-Fite (see here) is CF-101 (Piclidenoson) which is in Phase 2 & 3 trials for psoriasis, rheumatoid arthritis and other diseases.  Can-Fite is shortly to commence a Phase 2 trial of CF-101 … Continue reading →

I reported previously (see here) on the Namodenoson (CF102) liver cancer treatment from Israel’s Can-Fite. After Phase 2 testing, a supply of CF102 has been manufactured for “compassionate use” on critically ill patients at Rabin Medical Center in Petah Tikva. … Continue reading →

I reported previously (see here) on the small molecule treatments from Israel’s Can-Fite for psoriasis, liver and inflammatory diseases, and cancer. Can-Fite AND South Korea-based Kyongbo have just signed a distribution agreement for Can-Fite’s psoriasis treatment Piclidenoson (CF101). https://www.calcalistech.com/ctech/articles/0,7340,L-3767633,00.html

In advance of Phase 2 trials, preclinical data showed the potential efficacy of Namodenoson (CF102) from Israel’s Can-Fite (see Jan 2012).  It inhibited the growth and proliferation of liver fibrosis cells, supporting its potential ability to combat non-alcoholic fatty liver … Continue reading →

Israel’s Can-Fite BioPharma has announced positive results in its Phase IIb trial of their CF101 treatment for patients with active rheumatoid arthritis. http://www.globes.co.il/serveen/globes/docview.asp?did=1000903835&fid=1725

During trials by Israel’s Can-Fite BioPharma of its anti-inflammatory CF101 medication, the company discovered that the active ingredient is suitable for treating impotence. Can-Fite only found this out when they noticed that patients were not returning all the drugs at … Continue reading →

Israel’s Can-Fite BioPharma announced positive interim results of its Phase II/III clinical trial of CF101 for the treatment of psoriasis, and is continuing to enrol patients in the study. http://www.globes.co.il/serveen/globes/docview.asp?did=1000788461&fid=1725

Israel’s Can-Fite BioPharma has reported successful pre-clinical trials of CF101 for the treatment of anterior uveitis – the inflammation of the iris. An earlier trial found CF101 effective in treating posterior uveitis – inflammation of the retina. Uveitis is a … Continue reading →